Dr Landgren on the Rationale for Assessing Daratumumab Plus KRd in Newly Identified Myeloma

“The background of this study was based on the fact that modern combination therapies in [patients with] newly diagnosed multiple myeloma continue to deliver deep and durable responses reflected in high rates of MRD negativity, and this is found independent of transplant eligibility for patients in the newly diagnosed setting.”

C. Ola Landgren, MD, PhD, a professor and chief of the Division of Myeloma within the Department of Medicine on the University of Miami, Miller School of Medicine; director of the Sylvester Myeloma Institute; coleader of the Translational and Clinical Oncology Program; and the Paul J. DiMare Endowed Chair in Immunotherapy, mentioned the background and rationale for evaluating carfilzomib (Kyprolis), lenalidomide (Revlimid), and dexamethasone (KRd) with or with out daratumumab (Darzalex) for the therapy of sufferers with newly identified a number of myeloma.

The multicenter, randomized section 2 ADVANCE trial (NCT04268498), the design of which was introduced on the 2025 ASCO Annual Meeting, investigated the mix of daratumumab and KRd for the therapy of sufferers with newly identified a number of myeloma, Landgren started. He famous that within the a number of myeloma panorama, there are trendy mixture therapies, significantly within the newly identified setting. These advances proceed to reveal deep and sturdy responses and have been noticed by minimal residual illness (MRD) negativity, which has additionally been decided no matter transplant eligibility in sufferers with newly identified a number of myeloma, he added.

Additionally, MRD negativity is thought to be related to progression-free survival and general survival, and has not too long ago been established as an early finish level for accelerated approval, Langren continued. Specifically, outcomes from the April 2024 FDA Oncologic Drugs Advisory Committee assembly revealed that MRD could possibly be used as an finish point for accelerated approval in new remedies for sufferers with a number of myeloma.

Therefore, the rationale for ADVANCE is to doubtlessly provide one other potential normal of care choice for the therapy of sufferers with newly identified a number of myeloma that’s open to sufferers who’re transplant eligible, transplant ineligible, and transplant deferred.